Aprea Therapeutics (APRE) director receives new RSUs and stock options grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Aprea Therapeutics director John B. Henneman III received new equity awards. He was granted 3,135 restricted stock units on June 16, 2026, which will vest and settle in common stock on June 16, 2027, if he remains on the board. He also received stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 and expiring on June 16, 2036. Following these awards, he directly holds 13,364 shares of common stock, while the options and restricted stock units represent additional potential future ownership.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider HENNEMAN JOHN B III

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	12,555	$0.00	--
Grant/Award	Common Stock	3,135	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 12,555 shares (Direct, null); Common Stock — 13,364 shares (Direct, null)

Footnotes (1)

These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Key Figures

Restricted stock units granted: 3,135 units Stock options granted: 12,555 options Option exercise price: $0.7293 per share +3 more

6 metrics

Restricted stock units granted 3,135 units Granted June 16, 2026; vesting June 16, 2027

Stock options granted 12,555 options Granted June 16, 2026; vesting June 16, 2027

Option exercise price $0.7293 per share Stock Options (Right to Buy) for Aprea common stock

Option expiration date June 16, 2036 Expiration of granted stock options

Shares held after transaction 13,364 shares Common stock directly owned after grants

Underlying option shares 12,555 shares Common stock underlying the stock options

Key Terms

restricted stock units, Stock Options (Right to Buy, vesting, board of directors

4 terms

restricted stock units financial

"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Options (Right to Buy financial

"Stock Options (Right to Buy) with an exercise price of 0.7293 and expiration date of 2036-06-16"

vesting financial

"which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

board of directors financial

"subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/17/2026 - 07:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENNEMAN JOHN B III

(Last)

(First)

(Middle)

3805 OLD EASTON ROAD

(Street)

DOYLESTOWN

PENNSYLVANIA

18902

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aprea Therapeutics, Inc. [ APRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2026		A		3,135⁽¹⁾	A	$0.00	13,364	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$0.7293	06/16/2026		A		12,555		⁽²⁾	06/16/2036	Common Stock	12,555	$0.00	12,555	D

Explanation of Responses:

1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

2. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

	/s/ John Hamill, as Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Aprea Therapeutics (APRE) disclose in this Form 4 filing?

Aprea Therapeutics disclosed equity awards to director John B. Henneman III. He received 3,135 restricted stock units and stock options for 12,555 shares, both granted on June 16, 2026, subject to future vesting conditions tied to continued board service.

How many Aprea Therapeutics shares were granted to director John B. Henneman III?

John B. Henneman III was granted 3,135 restricted stock units in Aprea Therapeutics common stock. These units will vest and settle into common shares on June 16, 2027, provided he continues serving on the company’s board through the vesting date under the award’s terms.

What stock options did the Aprea Therapeutics director receive in this Form 4?

The director received options covering 12,555 shares of Aprea Therapeutics common stock. The options have an exercise price of $0.7293 per share, vest in full on June 16, 2027, and are scheduled to expire on June 16, 2036, if not exercised earlier.

When do the Aprea Therapeutics restricted stock units and options vest?

Both the 3,135 restricted stock units and the 12,555 stock options granted to the director vest on June 16, 2027. Vesting requires his continued service on Aprea Therapeutics’ board of directors through that date, with potential acceleration only under specified conditions in the award terms.

How many Aprea Therapeutics shares does the director hold after these awards?

After the reported transactions, John B. Henneman III directly holds 13,364 shares of Aprea Therapeutics common stock. This figure reflects his current share ownership, while the newly granted restricted stock units and stock options represent additional potential shares that depend on future vesting and, for options, exercise.

Are the Aprea Therapeutics equity awards to the director market purchases or compensation grants?

The Form 4 shows compensation-related grants to the director, not open-market purchases. Both the restricted stock units and stock options were awarded at no cash cost per share on grant, reflecting equity compensation tied to his ongoing board service with Aprea Therapeutics.